Related Experiment Video

Updated: May 20, 2026

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
06:43

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Published on: April 3, 2026

A novel EGFR mutation in exon 19 showed stable disease after TKI treatment

Anthonie J van der Wekken, Jos A Stigt, Nils A't Hart

    Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
    |July 17, 2012
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
    09:38

    Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

    Published on: June 26, 2019

    Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
    09:38

    Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

    Published on: August 11, 2017

    Related Experiment Videos

    Last Updated: May 20, 2026

    Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
    06:43

    Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

    Published on: April 3, 2026

    Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
    09:38

    Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

    Published on: June 26, 2019

    Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
    09:38

    Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

    Published on: August 11, 2017

    Related Concept Videos

    Mitogens and the Cell Cycle02:38

    Mitogens and the Cell Cycle

    Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...

    Articles linked to this work by shared authors, journal, and citation graph.

    Target Attainment and Clinical and Biochemical Parameters Associated with the Pharmacokinetics of 12 Tyrosine Kinase Inhibitors.

    Clinical pharmacokinetics·2026

    Diaphragm ultrasound and surface electromyography as predictors of clinical deterioration in acute exacerbations of COPD: a prospective observational study.

    ERJ open research·2026

    Structured Expert Elicitation of Long-Term Survival in Non-small Cell Lung Cancer: A Case Study Applying Guidance from NICE Technical Support Document 26.

    Applied health economics and health policy·2026

    Multidisciplinary tumor boards (MTBs) and survival Outcomes: Adherence to MTB recommendations in patients with lung cancer treated at two European cancer centers (AdThera-2).

    Lung cancer (Amsterdam, Netherlands)·2026

    Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Large language model-based approach for low-cost, rapid and accurate automated extraction of predictive biomarker testing results from Dutch pathology reports.

    Virchows Archiv : an international journal of pathology·2025

    Long-Term Benefit With First-Line Osimertinib Monotherapy in EGFR-Mutated Advanced NSCLC in the Era of Intensified First-Line Therapy.

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

    Integrated multi-omic profiling enables recurrence risk stratification beyond pathological stage in resected EGFR-mutant lung adenocarcinoma.

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

    Final Biomarker and Efficacy Analyses of Lorlatinib in Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer in a Phase 2 Study.

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

    Genomic and transcriptomic features of relapsed small cell lung cancer.

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

    Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB-IIIA Non-Small Cell Lung Cancer: Exploratory 8-year Overall Survival Landmark Update from the ADAURA Trial [161/175].

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

    The Evolution of Immunotherapy Revolution in Lung Cancer: A 20-Year Perspective.

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

    Do no harm? How health care management research can advance environmentally sustainable health care.

    Health care management review·2026

    Residue dissipation and dietary risk assessment of penconazole, bupirimate and its metabolite ethirimol in grapes using UPLC-MS/mS.

    Journal of environmental science and health. Part. B, Pesticides, food contaminants, and agricultural wastes·2026

    Reasoned opinion on setting of an MRL for copper compounds in wild game.

    EFSA journal. European Food Safety Authority·2026

    [Spatio-temporal Characteristics and Influencing Factors of the Coordinated Treatment Cost of Pollution Reduction and Carbon Reduction in China].

    Huan jing ke xue= Huanjing kexue·2025

    ECT10 is an m6A reader that negatively regulates the drought stress response in Arabidopsis by modulating mRNA stability.

    The Plant journal : for cell and molecular biology·2025

    Analysis of intellectual and thematic progress of the Journal of Environmental Management - Section V: Environmental Policy, Economics, and Social Science.

    Journal of environmental management·2025
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us